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http://dx.doi.org/10.1016/j.jmii.2014
1684-1182/Copyright ª 2014, TaiwanBackground: The emergence of carbapenem-resistant Acinetobacter baumannii (CRAB) com-
plex has posed a great challenge to clinicians worldwide. Sitafloxacin has been shown to have
in vitro activity against pathogens resistant to other fluoroquinolones. However, data
comparing the anti-CRAB activity of sitafloxacin with that of other antimicrobial agents are
limited.
Methods: Genospecies were identified by 16Se23S ribosomal RNA intergenic spacer
sequencing. Minimum inhibitory concentrations (MICs) were determined by an agar dilution
method. Isolates with sitafloxacin MICs 2 mg/L were provisionally considered as susceptible
to sitafloxacin. The MIC breakpoint for tigecycline susceptibility was 2 mg/L.
Results: A total of 167 CRAB complex blood isolates (146 A. baumannii, 7 Acinetobacter pittii,
and 14 Acinetobacter nosocomialis) were collected from January 2009 to December 2011.
Around 90% of the A. baumannii isolates were resistant to amikacin, cefepime, ceftazidime,
piperacillin/tazobactam, ampicillin/sulbactam, ciprofloxacin, and levofloxacin. By contrast,
the rate of resistance to colistin, sitafloxacin, and tigecycline was relatively low (0%, 41.1%,
and 65.1%, respectively). The MIC50 and MIC90 of ciprofloxacin, levofloxacin, and sitafloxacin
were 128 mg/L and >128 mg/L; 16 mg/L and 64 mg/L; 2 mg/L and 8 mg/L, respectively.
Compared with ciprofloxacin and levofloxacin, sitafloxacin had a significantly lower MICt of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100,
l.com (Y.-C. Chuang).
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546 Y.-S. Huang et al.Table 1 Antimicrobial suscepti
isolates
Antimicrobial agent
Rang
Imipenem 0.2
Meropenem 0.2
Ampicillin/sulbactam 0.
Piperacillin/tazobactam 0.0
Cefepime
Ceftazidime
Amikacin
Ciprofloxacin 0.2
Levofloxacin 0.12
Sitafloxacin 0.01
Colistin 0.
Tigecycline 0.2
Rifampin
MIC Z minimum inhibitory concen
a Susceptibility rate compared be(p < 0.001), and the rate of resistance to sitafloxacin was significantly lower than that to cip-
rofloxacin (97.9% vs. 41.1%, p < 0.001), levofloxacin (97.3% vs. 41.1%, p < 0.001), and tigecy-
cline (p < 0.001).
Conclusion: Sitafloxacin has acceptable in vitro activity against CRAB, even against isolates
resistant to other fluoroquinolones. Sitafloxacin may be considered an alternative drug of
choice in treating CRAB related infections.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The emergence of carbapenem-resistant Acinetobacter
baumannii (CRAB) complex has posed a great challenge to
clinicians worldwide, complicating the management of
nosocomial infections,1 in particular A. baumannii in-
fections.2 The therapeutic option for CRAB is generally
limited to colistin and tigecycline.2,3 Colistin and tigecy-
cline have been shown to have good in vitro activity against
A. baumannii pneumonia isolates, even CRAB pneumonia
isolates.4,5 However, poor pulmonary penetration6 and
renal toxicity are major concerns of colistin use.7,8 Mean-
while, the resistance of A. baumannii to tigecycline is
emerging,9,10 and the low serum level of tigecycline limits
it use in bacteremic patients.11
Fluoroquinolones are commonly used antimicrobial
agents. They have broad-spectrum activity against both
Gram-negative and -positive pathogens.12 Nowadays,
resistance to fluoroquinolones in most nosocomial isolates
of A. baumannii may be attributed to mutations of the gyrA
and parC genes.13,14 Fluoroquinolones have thus become a
less than ideal treatment for CRAB-related infection. Sita-
floxacin has been shown to have good in vitro activity
against pathogens resistant to other fluoroquinolones.15,16bility results of 167 bacterem
A. baumannii (n Z 1
MIC (mg/L)
e MIC50 MIC90
5e128 48 128
5e>128 32 128
5e128 16 64
6e>128 >128 >128
4e>128 128 >128
8e>128 >128 >128
2e>128 >128 >128
5e>128 128 >128
5e128 16 64
5e16 2 8
5e2 1 2
5e16 4 16
1e>128 8 16
tration; n.a. Z not applicable
tween different genospecies.The rate of CRAB susceptibility to sitafloxacin was
deemed acceptable by one report.17 Genospecies 2 (A.
baumannii) has been associated with greater resistance to
antimicrobial agents as well as higher mortality rates in
bacteremic patients.18e20 Because Thamlikitkul et al17 did
not identify the genospecies of A. baumannii complex in
their study, they may have overestimated the susceptibility
of A. baumannii to sitafloxacin.
Because data comparing antimicrobial susceptibilities
between sitafloxacin and other antimicrobial agents against
genospecies identified as CRAB are lacking, our study aimed
to evaluate and compare the susceptibility of bacteremic
patient-derived CRAB complex isolates to sitafloxacin
versus other antimicrobial agents especially other
fluoroquinolones.Methods
Hospital setting and bacterial isolates
This study was conducted at the National Taiwan University
Hospital (NTUH). NTUH is a 2200-bed teaching hospital
located in Taipei, Taiwan. It provides both primary andic carbapenem-resistant Acinetobacter baumannii complex
46) Acinetobacter pittii (n Z 7)
Rate of
susceptibility
(%)
MIC (mg/L)
Range MIC50 MIC90
11.6 0.25e128 64 128
3.4 2e>128 32 >128
14.4 0.5e64 2 64
1.4 16e>128 64 >128
2.1 64e>128 128 >128
2.1 32e>128 >128 >128
12.3 4e>128 64 >128
2.1 0.25e128 0.5 128
2.7 0.25e64 0.5 64
58.9 0.06e4 0.06 4
100 0.5e1 1 1
34.9 0.5e4 1 4
33.6 4e16 8 16
.
Sitafloxacin activity against CRAB 547tertiary medical care. From January 2009 to December
2011, bacteremic isolates of CRAB complex were prospec-
tively collected at the NTUH. Isolates were cultured from
blood in the microbiological laboratory using the Bactec
9240 system (Becton Dickson, Sparks, MD, USA) during the
study period.
Bacterial and genospecies identification
Biochemical methods were used to identify isolates of the
A. baumannii complex.21 The Vitek-2 bacterial identifica-
tion system was used to confirm the identity of the isolates
and sequencing of the 16Se23S ribosomal RNA (rRNA) gene
intergenic spacer (ITS) region was used to identify geno-
species as previously described.22 The identified genospe-
cies were classified as A. baumannii, Acinetobacter pittii,
or Acinetobacter nosocomialis. Other genospecies or un-
identified genospecies were excluded.
Antimicrobial susceptibility testing
Carbapenem resistance was defined as isolates resistant
to imipenem or meropenem as determined using the disc
diffusion method described by the Clinical and
Laboratory Standards Institute (CLSI).23
An agar dilution method was used to determine amikacin,
cefepime, ceftazidime, imipenem, meropenem, ampi-
cillin/sulbactam, piperacillin/tazobactam, colistin, cipro-
floxacin, levofloxacin, tigecycline, rifampin, and
sitafloxacin minimum inhibitory concentrations (MICs) for
CRAB complex isolates defined by CLSI criteria.23 The
testing results of tigecycline susceptibility was interpreted
by the US Food and Drug Administration breakpoint for
Enterobacteriaceae susceptibility to tigecycline.24 The
rifampin breakpoints of for A. baumannii were as published
by the French Society for Microbiology.25 Isolates withAcinetobacter nosocomialis (n Z 14)
Rate of
susceptibility
(%)
MIC (mg/L) Rat
suscep
(
Range MIC50 MIC90
28.6 0.25e128 8 64 21.4
28.6 16e128 16 128 0
71.4 0.5e64 5 64 50
14.3 0.015e>128 >128 >128 28.6
0 2e128 8 128 57.1
0 4e>128 8 >128 64.3
14.3 2e>128 4 >128 64.3
57.1 0.125e>128 0.375 >128 64.3
57.1 0.125e16 0.25 16 78.6
85.7 0.015e4 0.06 4 78.6
100 0.5e2 1 2 100
85.7 0.25e16 1 8 71.4
28.6 1e32 8 16 42.9rifampin MICs of 4 mg/L or tigecycline MICs of 2 mg/L
were considered susceptible. Isolates with sitafloxacin MICs
2 mg/L were provisionally considered to be susceptible.26
The testing results of the other antibiotics were interpreted
according to the CLSI criteria.Statistical analysis
The associations between MICs and rates of resistance of
different A. baumannii complex genospecies or between
MICs and resistance to different fluoroquinolones were
compared using KruskaleWallis one-way analysis of vari-
ance (ANOVA), or Fisher’s exact test. Posthoc analysis using
the ManneWhitney U test or Fisher exact test utilized a
modified Bonferroni-adjusted a for pair-wise comparisons if
the result of the initial KruskaleWallis one-way ANOVA or
Fisher’s exact test was statistically significant. Data were
analyzed using Stata software, version 12 (StataCorp, Col-
lege Station, TX, USA).Results
The MIC distribution and antimicrobial
susceptibility of 167 CRAB complex isolates
We collected 167 CRAB complex isolates, including 146
(87.4%) A. baumannii, seven (4.2%) A. pittii, and 14 (8.4%)
A. nosocomialis isolates. All of the isolates were derived
from patients with bacteremia. The antimicrobial suscep-
tibility testing results are listed in Table 1. Overall, colistin
possessed the best in vitro activity with 100%, 61.7%, 40.1%,
and 34.1% of the 167 CRAB complex isolates being suscep-
tible to colistin, sitafloxacin, tigecycline, and rifampin,
respectively.pa
e of
tibility
%)
Overall A. baumannii
vs. A. pittii
A. baumannii
vs. A. nosocomialis
0.2 0.21 0.39
0.04 0.03 0.99
<0.001 0.002 0.004
<0.001 0.13 0.001
<0.001 0.99 <0.001
<0.001 0.99 <0.001
<0.001 0.99 <0.001
<0.001 <0.001 <0.001
<0.001 <0.001 <0.001
0.19 0.24 0.25
n.a. n.a. n.a.
0.001 0.011 0.01
0.75 0.99 0.56
548 Y.-S. Huang et al.The percentage of A. baumannii isolates susceptible to
colistin, sitafloxacin, tigecycline, and rifampin was higher
(100%, 58.9%, 34.9%, and 33.6% respectively; Table 1) than
that to amikacin, ceftazidime, cefepime, ampicillin/sul-
bactam, piperacillin/tazobactam, ciprofloxacin, and levo-
floxacin (all <15%). The percentage of isolates susceptible
to sitafloxacin was significantly higher than that susceptible
to tigecycline (58.9% vs. 34.9%, p < 0.001).
Compared with A. pittii isolates, A. baumannii isolates
showed higher ampicillin/sulbactam, ciprofloxacin, levo-
floxacin, and tigecycline resistance (all p < 0.05).
Compared with A. nosocomialis isolates, A. baumannii
isolates showed higher resistance to all tested antimi-
crobial agents (all p < 0.05) except sitafloxacin and
rifampin. The percentage of A. baumannii, A. pittii, and
A. nosocomialis isolates susceptible to sitafloxacin was
similar (58.9%, 85.7%, and 78.6%, respectively, p Z 0.19;
Table 1).The MIC distribution and antimicrobial
susceptibility of 100 tigecycline-resistant CRAB
complex isolates
The drug susceptibility of CRAB and tigecycline-resistant
CRAB isolates was of interest. Among 167 CRAB complex
isolates, 100 were tigecycline resistant, including 95 A.
baumannii isolates, one A. pittii isolate, and four A.
nosocomialis isolates. All 100 tigecycline-resistant iso-
lates were susceptible to colistin, which remained the
most active agent (100% susceptibility rate). The per-
centage of the 95 A. baumannii isolates susceptible to
sitafloxacin and rifampin was 51.6% and 28.4%, respec-
tively, whereas the percentage susceptible to amikacin,
ceftazidime, cefepime, ampicillin/sulbactam, piper-
acillin/tazobactam, ciprofloxacin, and levofloxacin was
only around 10% (Table 2).Comparison of the in vitro activity of the three
fluoroquinolones
Table 3 shows the MIC distributions of three different flu-
oroquinolones. Of the A. baumannii isolates, the MIC50,
MIC90, and geometric means of the MICs of ciprofloxacin,
levofloxacin, and sitafloxacin were 128 mg/L, >128 mg/L,
96.3 mg/L; 16 mg/L, 64 mg/L, 14.6 mg/L; 2 mg/L, 8 mg/L,
and 2.7 mg/L, respectively. Fig. 1 depicts the distribution
of ciprofloxacin, levofloxacin, and sitafloxacin MICs in terms
of cumulative probability. The MICs of the three fluo-
roquinolones differed. The sitafloxacin MIC was significantly
lower than that of the two comparator fluoroquinolones
(p < 0.001). The rate of susceptibility to sitafloxacin was
significantly higher than that to ciprofloxacin and levo-
floxacin [2.1% vs. 58.9% (p < 0.001) and 2.7% vs. 58.9%
(p < 0.001), respectively] and the MIC of sitafloxacin was
significantly lower than that of the comparator fluo-
roquinolones in A. nosocomialis isolates (ciprofloxacin vs.
sitafloxacin, p Z 0.006; levofloxacin vs. sitafloxacin,
p Z 0.02).Discussion
Our results indicate that, after colistin, sitafloxacin is the
second most effective antibiotic against CRAB complex
blood isolates and tigecycline-resistant CRAB blood iso-
lates. Compared with ciprofloxacin and levofloxacin, sita-
floxacin had the lowest MIC value and resistance rate.
This is the first study focused on the in vitro activity of
sitafloxacin against genospecies-identified CRAB complex
isolates from bacteremic patients. A similar report from
Thailand showed that the MIC range, MIC50, and MIC90
values of sitafloxacin for 258 CRAB complex isolates were
0.016e4 mg/L, 1 mg/L, and 2 mg/L, respectively.17 By using
2 mg/L as the MIC breakpoint for susceptibility, 91.4% of
these isolates were susceptible to sitafloxacin in that study.
The MIC range, MIC50, MIC90 in our genospecies-identified
CRAB isolates (0.015e16 mg/L, 2 mg/L, 8 mg/L, respec-
tively) were higher and the susceptibility rate was lower
(91.4% vs. 58.9%). Because genospecies was not taken into
consideration by that study, the rate of susceptibility to
sitafloxacin might have been overestimated. In addition,
the isolates in our study were all from patients with
bacteremia, whereas those reported by Thamlikitkul et al17
were from patients with lower respiratory tract infection,
urinary tract infection, or bacteremia. Therefore the clin-
ical significance of our findings may be different.
Colistin and tigecycline are the main therapeutic options
for CRAB complex.2 Our study confirmed that colistin has
excellent in vitro activity. As for tigecycline, the suscep-
tibility of A. baumannii isolates (rate, 34.9%) was much
lower than that of A. pittii (85.7%) and A. nosocomialis
(71.4%). This highlights the importance of MIC confirmation
and genospecies identification when treating CRAB infec-
tion. Resistance of A. baumannii to tigecycline is
emerging,9,10 and simultaneous resistance to colistin,
rifampicin, and tigecycline has been reported.27 Sita-
floxacin could be an option in such cases.
Compared with other fluoroquinolones, sitafloxacin has
better in vitro activity against Gram-positive cocci,28,29
Enterobacteriaceae,29,30 other nonfermentative species,29
and even some quinolone-resistant bacteria.16,31,32 Our
study is the first to report the superior in vitro activity of
sitafloxacin against CRAB. This advantage of sitafloxacin
may be due to its ability to inhibit both DNA gyrase and
topoisomerase IV,33,34 or to overcome plasmid-mediated
quinolone resistance.35 Compared to other fluo-
roquinolones, sitafloxacin also has a greater affinity for DNA
gyrase36 and inhibits at a lower concentration.37
In Taiwan, Chiu et al38 have investigated mechanisms of
quinolone-resistance in A. baumannii clinical isolates. They
reported that the expression of AdeB, an efflux pump pro-
tein, is associated with resistance to ciprofloxacin in A.
baumannii and that multiple mutations in gyrA and parC
genes also play a role.38 Because several mechanisms of
quinolone-resistance exist in A. baumannii, it is unknown
whether sitafloxacin could have good clinical efficacy
against CRAB. Sitafloxacin is presently available only in oral
form, which limits its use in patients with poor gastroin-
testinal absorption or who are critically ill. However, it still
has great potential for patients with less severe diseases,
switching from parenteral to oral antibiotics, or
Table 2 Antimicrobial susceptibility results of 100 tigecycline- and carbapenem-resistant Acinetobacter baumannii complex
isolates
Antimicrobial
agent
A. baumannii (n Z 95) Acinetobacter pittii
(n Z 1)
Acinetobacter nosocomialis
(n Z 4)
MIC (mg/L) MIC (mg/L) MIC (mg/L)
Range MIC50 MIC90 Rate of
susceptibility
(%)
MIC Rate of
susceptibility
(%)
Range MIC50 Rate of
susceptibility
(%)
Imipenem 0.25e128 64 128 11.6 128 0 0.25e64 48 25
Meropenem 2e128 32 128 2.1 >128 0 16e128 128 0
Ampicillin/
sulbactam
0.5e64 16 64 12.6 64 0 0.5e64 48 25
Piperacillin/
tazobactam
128e>128 >128 >128 0 >128 0 >128e>128 >128 0
Cefepime 8e>128 128 >128 1.1 >128 0 64e128 96 0
Ceftazidime 64e>128 128 >128 0 >128 0 16e>128 16 0
Amikacin 2e>128 >128 >128 11.6 >128 0 4e64 64 25
Ciprofloxacin 16e>128 128 >128 0 128 0 2e>128 64 0
Levofloxacin 0.25e128 16 64 1.1 64 0 2e16 16 25
Sitafloxacin 1e16 2 8 51.6 4 0 0.5e4 4 25
Colistin 0.5e2 1 1 100 0.5 100 1e2 1 100
Tigecycline 4e16 4 16 0 4 0 8e16 8 0
Rifampin 1e>128 8 16 28.4 16 0 1e16 10 50
MIC Z minimum inhibitory concentration.
Sitafloxacin activity against CRAB 549combination therapy in treating CRAB-related infection. It
is worth noting that the resistance rate of CRAB to sita-
floxacin (41.1%) is relatively high compared to colistin (0%)
in our study. Therefore, empirically using sitafloxacin for
CRAB infection without susceptibility test results is not
suggested.
Our study has several limitations. First, the number of A.
pittii and A. nosocomialis isolates is small, which might notTable 3 Distribution of ciprofloxacin, levofloxacin, and sitaflo
carbapenem-resistant Acinetobacter baumannii complex isolates
MIC (mg/L)
Range MIC50 MIC90 Geometric
mean
A. baumannii complex (n Z 167)
Ciprofloxacin 0.125e>128 128 >128 59.64
Levofloxacin 0.125e128 8 64 10.26
Sitafloxacin 0.015e16 2 8 1.92
A. baumannii (n Z 146)
Ciprofloxacin 0.25e>128 128 >128 96.3
Levofloxacin 0.125e128 16 64 14.6
Sitafloxacin 0.015e16 2 8 2.7
Acinetobacter pittii (n Z 7)
Ciprofloxacin 0.25e128 0.5 128 3
Levofloxacin 0.25e64 0.5 64 1.8
Sitafloxacin 0.06e4 0.06 4 0.3
Acinetobacter nosocomialis (n Z 14)
Ciprofloxacin 0.125e>128 0.375 >128 1.8
Levofloxacin 0.125e16 0.25 16 0.64
Sitafloxacin 0.015e4 0.06 4 0.1
a Rate of susceptibility rate compared between different genospecireflect the true difference between genospecies. Second,
there is no standardized MIC breakpoint for susceptibility of
Acinetobacter species to tigecycline, sitafloxacin, or
rifampin. With different MIC cut-off values, the rate of
CRAB susceptibility to the above agents might change.
Third, our study included only one medical center and had a
relatively short duration. Because the epidemiology of
CRAB varies widely among institutes and countries, thexacin minimum inhibitory concentrations (MICs) among 167
Rate of
susceptibility
(%)
pa
Overall Ciprofloxacin vs.
sitafloxacin
Levofloxacin vs.
sitafloxacin
9.6
11.4 <0.001 <0.001 <0.001
61.7
2.1
2.7 <0.001 <0.001 <0.001
58.9
57.1
57.1 0.60 0.56 0.56
85.7
64.3
78.6 0.74 0.68 0.99
78.6
es.
Figure 1. Cumulative plot of the distribution of ciprofloxa-
cin, levofloxacin, and sitafloxacin MICs for (A) 146 carbapenem-
resistant Acinetobacter baumannii isolates, and (B) 95
tigecycline-resistant A. baumannii isolates.
550 Y.-S. Huang et al.results of this single-center study might not be generaliz-
able, nor could it reflect the detailed resistant pattern in
Taiwan. Ideally, CRAB complex isolates from multiple cen-
ters with a longer study period would be more represen-
tative. Last, the mechanisms responsible for differences in
MIC distribution or resistance rate among different fluo-
roquinolones are not examined in the present study, and
warrant further investigation.
In conclusion, sitafloxacin has an acceptable in vitro ac-
tivity againstCRABcomplex isolates,even isolates resistant to
tigecycline or other fluoroquinolones and genospecies iden-
tified as A. baumannii. Because the nephrotoxicity of colistin
is a concern, sitafloxacin can be considered an alternative
drug of choice for CRAB-related infections. However, further
studies are needed to determine the clinical efficacy of sita-
floxacin in treating CRAB-related infections.
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